Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep Cost

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Nov 12, 2022 7:34pm

234 Views

Post# 35094218

RE:RE:Pelareorep Cost

Thanks ksw.

I recall the same basic discussion.

I think Brad, our former fealess (and feckless) former leader, said ONCY had spent $100 mil on getting production completely nailed down.

I think it is produced at a vaccine manufacturer in California that is owned by or related to a big pharma, maybe Pfizer.

<< Previous

Bullboard Posts

Next >>

Mid-year update: Charting GameSquare’s sharp business growth